Cite
Patient adherence to fully reimbursed proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9i) treatment
MLA
Alissia Stummer, et al. “Patient Adherence to Fully Reimbursed Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor (PCSK9i) Treatment.” Wiener Klinische Wochenschrift, Feb. 2023. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........c6a09b0fedfe3a1665198bd29ac3ca49&authtype=sso&custid=ns315887.
APA
Alissia Stummer, Robin Ristl, Bernhard Kogler, Melanie Muskovich, Michael Kossmeier, & Thomas M. Stulnig. (2023). Patient adherence to fully reimbursed proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9i) treatment. Wiener Klinische Wochenschrift.
Chicago
Alissia Stummer, Robin Ristl, Bernhard Kogler, Melanie Muskovich, Michael Kossmeier, and Thomas M. Stulnig. 2023. “Patient Adherence to Fully Reimbursed Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor (PCSK9i) Treatment.” Wiener Klinische Wochenschrift, February. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........c6a09b0fedfe3a1665198bd29ac3ca49&authtype=sso&custid=ns315887.